[4-(Hydroxymethyl)phenyl]methyl methanesulfonate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [4-(Hydroxymethyl)phenyl]methyl methanesulfonate
• 英文别名: [4-(hydroxymethyl)phenyl]methyl methanesulfonate
• 化学式: C₉H₁₂O₄S
• 分子量: 216.26
• InChiKey: VVOAVNQUXGUIRB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  72
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• METHOD FOR PREPARING SUBSTITUTED PHENYLACETIC ACID DERIVATIVE
  申请人：Jiangsu Ruike Medical Science And Technology Co., Ltd.

  公开号：EP3680227A1

  公开（公告）日：2020-07-15

  The invention belongs to the pharmaceutical manufacturing field, which relates to a novel process for the preparation of substituted phenylacetic acids derivatives, especially relates to the preparation of 2-(4-(2-oxocyclopentyl)phenyl)propanoic acid. The process for the preparation of the precursor form of loxoprofen which use 1,4-di-halobenzylcompounds or disubstituted benzyl compounds as starting material, is through the substitution reaction of cyclopentanone groups or its precursor compounds. Wherein X is halogen, L1 is a suitable leaving group selected from halogen, OH, OMs, OTs, OTf and the like; L2 is a suitable leaving group selected from halogen, CN, OH, -CH2OH, -CHO, CH3NO2, ester group, -NR4R5, OTf, OTs, OMs, -C=CR6, -C≡CR7 and the like, wherein R4, R5, R6, R7 are short chain alkyl groups; Z is cyclopentanone group and its precursor form selected from and the like; R3 is short chain alkyl groups. L3 is a suitable leaving group selected from halogen , OH, OMs, OTs, OTf and the like, or organometallic groups. The invention also include the detailed procedure to convert the precursor compounds of cyclopentanone group to cyclopentanone, followed by the transformation of the precursor compounds of loxoprofen to loxoprofen.

  本发明属于医药生产领域，涉及一种新的取代苯乙酸衍生物的制备工艺，尤其涉及2-(4-(2-氧代环戊基)苯基)丙酸的制备工艺。以 1,4-二-卤代苄基化合物或二取代苄基化合物为起始原料，通过环戊酮基团或其前体化合物的取代反应，制备络索洛芬的前体形式。 其中，X 是卤素，L1 是选自卤素、OH、OMs、OTs、OTf 及类似物的合适离去基团；L2 是选自卤素、CN、OH、-CH2OH、-CHO、CH3NO2、酯基、-NR4R5、OTf、OTs、OMs、-C=CR6、-C≡CR7 及类似物的合适离去基团，其中 R4、R5、R6、R7 是短链烷基；Z 是选自以下的环戊酮基团及其前体形式 等；R3 是短链烷基。L3 是合适的离去基团，选自卤素、OH、OMs、OTs、OTf 等或有机金属基团。本发明还包括将环戊酮基团的前体化合物转化为环戊酮，然后将洛索洛芬的前体化合物转化为洛索洛芬的详细步骤。